Active component

Active Component is a pharmaceutical company that specializes in the development and production of active pharmaceutical substances (APIs) using the latest technologies and equipment.

History

2023: Protek acquired 44.7% of Active Component

On May 16, 2023, it became known that the Protek group of companies, the main owner of which is Russian businessman Vadim Yakunin, acquired a share of 44.7% in the manufacturer of Active Ingredient pharmaceutical substances.

It is noted that in March 2023, Anvilab LLC, as part of Protek, became the owner of a 19.6 percent stake in Vega LLC, the parent company of Active Component. As part of the new deal, the amount of which is not reported, the share was brought to 44.7%. Another 41% in Vega retained the Active Component, and the remaining part was divided by the founders of this enterprise - Alexander Semenov (7.9%) and Zievuddin Khodzhaev (6.4%).

Protek acquired a 44.7% stake in the manufacturer of Active Ingredient pharmaceutical substances

As stated on the Active Component website, the company joins forces with leading Russian and foreign pharmaceutical companies in order to "provide people with locally produced drugs in various fields of medicine." These are cardiological and antiviral agents, as well as antibiotics. As part of a partnership with Protec, seven new projects will be launched with a total investment of about 2.7 billion rubles. One of them provides for the construction of a plant for the production of intermediates.

The emergence of a new enterprise will help Active Component to fill the shortage of certain raw materials, the supply of which was reduced due to the current geopolitical situation. Cooperation with Protec will also improve performance against the background of falling sales of some antiviral drugs, in particular, funds to combat COVID-19.

We entered this year in partnership with the Protek group of companies and are very pleased with the development of our relationship. Accordingly, we will move towards the added value of selling full-cycle positions. Because, in my opinion, this is exactly the global strategic prospect of increasing profitability, "Semenov said.[1]

Notes